Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument

REFERENCES

1. 1.↵
   1. Sjogren RW

   . Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265–82.

   OpenUrlPubMed
2. 2.↵
   1. Lock G,
   2. Holstege A,
   3. Lang B,
   4. Scholmerich J

   . Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997;92:763–71.

   OpenUrlPubMed
3. 3.↵
   1. Nietert PJ,
   2. Mitchell HC,
   3. Bolster MB,
   4. Curran MY,
   5. Tilley BC,
   6. Silver RM

   . Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol 2005;32:51–7.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Gliddon AE,
   2. Dore CJ,
   3. Maddison PJ

   . Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006;55:473–9.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Khanna D,
   2. Hays RD,
   3. Maranian P,
   4. Seibold JR,
   5. Impens A,
   6. Mayes MD,
   7. et al.

   Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257–63.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Jaeschke R,
   2. Singer J,
   3. Guyatt GH

   . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407–15.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Crosby RD,
   2. Kolotkin RL,
   3. Williams GR

   . Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395–407.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Bodukam V,
   2. Hays RD,
   3. Maranian P,
   4. Furst DE,
   5. Seibold JR,
   6. Impens A,
   7. et al.

   Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology 2011;50:330–4. Epub 2010 Sep 30.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Khanna D,
   2. Hays RD,
   3. Park GS,
   4. Braun-Moscovici Y,
   5. Mayes MD,
   6. McNearney TA,
   7. et al.

   Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 2007;57:1280–6.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Revicki D,
    2. Hays RD,
    3. Cella D,
    4. Sloan J

    . Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102–9.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Fayers P,
    2. Hays RD

    1. Hays RD

    . Reliability and validity (including responsiveness). In: Fayers P, Hays RD, editors. Assessing quality of life in clinical trials. 2nd ed. New York: Oxford; 2005:25–39.
12. 12.↵
    1. Hays RD,
    2. Farivar S,
    3. Liu H

    . Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD 2005;2:63–7.

    OpenUrl
13. 13.↵
    1. Hays RD,
    2. Brodsky M,
    3. Johnston MF,
    4. Spritzer KL,
    5. Hui KK

    . Evaluating the statistical significance of health-related quality-of-life change in individual patients. Eval Health Prof 2005;28:160–71.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Khanna D,
    2. Pope JE,
    3. Khanna PP,
    4. Maloney M,
    5. Samedi N,
    6. Norrie D,
    7. et al.

    The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. J Rheumatol 2008;35:2339–43.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Sloan JA,
    2. Cella D,
    3. Hays RD

    . Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 2005;58:1217–9.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Khanna D,
    2. Furst DE,
    3. Wong WK,
    4. Tsevat J,
    5. Clements PJ,
    6. Park GS,
    7. et al.

    Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 2007;16:1083–92.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Crosby RD,
    2. Kolotkin RL,
    3. Williams GR

    . Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395–407.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Revicki DA,
    2. Cella D,
    3. Hays RD,
    4. Sloan JA,
    5. Lenderking WR,
    6. Aaronson NK

    . Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006;4:70.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Wells GA,
    2. Li T,
    3. Maxwell L,
    4. Maclean R,
    5. Tugwell P

    . Responsiveness of patient reported outcomes including fatigue, sleep quality and activity limitation and quality of life following treatment with abatacept in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:260–51.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Khanna PP,
    2. Maranian P,
    3. Gregory J,
    4. Khanna D

    . The minimally important difference and patient acceptable symptom state for the Raynaud’s Condition Score in patients with Raynaud’s phenomenon in a large randomized controlled clinical trial. Ann Rheum Dis 2010;69:588–910.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Hirsch JD,
    2. Lee SJ,
    3. Terkeltaub R,
    4. Khanna D,
    5. Singh J,
    6. Sarkin A,
    7. et al.

    Evaluation of an instrument assessing influence of gout on health-related quality of life. J Rheumatol 2008;35:2406–14.

    OpenUrlAbstract/FREE Full Text